Literature DB >> 14687488

Expression of hypoxia-inducible factor 1alpha in human normal, benign, and malignant prostate tissue.

Zhenxian Du1, Chisato Fujiyama, Yongxin Chen, Zenjiro Masaki.   

Abstract

OBJECTIVE: To investigate hypoxia-inducible factor 1alpha (HIF-1alpha) protein expression in normal prostates (NP), benign prostatic glandular hyperplasia (BPH), and prostate adenocarcinoma (Pca).
METHODS: HIF-1alpha protein expression was determined by immunohistochemistry in formalin-fixed and paraffin-embedded specimens obtained from 13 cases of NP, 28 cases of BPH, and 34 cases of Pca. In cases of Pca, the relationship between HIF-1alpha protein expression and certain clinicopathological factors, such as clinicopathologic stage and Gleason score, was evaluated.
RESULTS: NP manifested no immunoreactivity, whereas Pca and BPH showed significantly increased HIF-1alpha protein expression. A significantly higher expression was observed in Pca specimens compared with BPH samples. In Pca, no significant relationship between HIF-1alpha protein expression and clinicopathological factors was found.
CONCLUSION: Our findings of increased HIF-1alpha protein expression in BPH and Pca specimens suggests the potential role of this protein in BPH and Pca.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14687488

Source DB:  PubMed          Journal:  Chin Med J (Engl)        ISSN: 0366-6999            Impact factor:   2.628


  16 in total

1.  Investigation on tumor hypoxia in resectable primary prostate cancer as demonstrated by 18F-FAZA PET/CT utilizing multimodality fusion techniques.

Authors:  Rita Garcia-Parra; David Wood; Rajal B Shah; Javed Siddiqui; Hero Hussain; Hyunjin Park; Timothy Desmond; Charles Meyer; Morand Piert
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-07-16       Impact factor: 9.236

Review 2.  Imaging angiogenesis of genitourinary tumors.

Authors:  Ying-Kiat Zee; James P B O'Connor; Geoff J M Parker; Alan Jackson; Andrew R Clamp; M Ben Taylor; Noel W Clarke; Gordon C Jayson
Journal:  Nat Rev Urol       Date:  2010-01-19       Impact factor: 14.432

Review 3.  Hypoxia-Induced Signaling Promotes Prostate Cancer Progression: Exosomes Role as Messenger of Hypoxic Response in Tumor Microenvironment.

Authors:  Gagan Deep; Gati K Panigrahi
Journal:  Crit Rev Oncog       Date:  2015

4.  Normoxic regulation of HIF-1α in prostate cancer.

Authors:  Weranja K B Ranasinghe; Graham S Baldwin; Arthur Shulkes; Damien Bolton; Oneel Patel
Journal:  Nat Rev Urol       Date:  2014-07-01       Impact factor: 14.432

Review 5.  Recent developments in prostate cancer biomarker research: therapeutic implications.

Authors:  Sujitra Detchokul; Albert G Frauman
Journal:  Br J Clin Pharmacol       Date:  2011-02       Impact factor: 4.335

6.  Enzyme-linked immunosorbent assay for pharmacological studies targeting hypoxia-inducible factor 1alpha.

Authors:  J L Formento; E Berra; B Ferrua; N Magné; G Simos; C Brahimi-Horn; J Pouysségur; G Milano
Journal:  Clin Diagn Lab Immunol       Date:  2005-05

Review 7.  Angiogenesis inhibitors in the treatment of prostate cancer.

Authors:  Paul G Kluetz; William D Figg; William L Dahut
Journal:  Expert Opin Pharmacother       Date:  2010-02       Impact factor: 3.889

Review 8.  Recent advances in annular pathobiology provide insights into rim-lesion mediated intervertebral disc degeneration and potential new approaches to annular repair strategies.

Authors:  James Melrose; Susan M Smith; Christopher B Little; Robert J Moore; Barrie Vernon-Roberts; Robert D Fraser
Journal:  Eur Spine J       Date:  2008-06-27       Impact factor: 3.134

Review 9.  Targeting vasculature in urologic tumors: mechanistic and therapeutic significance.

Authors:  Shinichi Sakamoto; A Jacqueline Ryan; Natasha Kyprianou
Journal:  J Cell Biochem       Date:  2008-02-15       Impact factor: 4.429

10.  Modulatory effect of silymarin on inflammatory mediators in experimentally induced benign prostatic hyperplasia: emphasis on PTEN, HIF-1α, and NF-κB.

Authors:  Reem T Atawia; Hala H Mosli; Mariane G Tadros; Amani E Khalifa; Hisham A Mosli; Ashraf B Abdel-Naim
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-08-28       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.